| GSK692342 / GSK, Bill & Melinda Gates Foundation |
NCT06062238: Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults |
|
|
| Recruiting | 3 | 20000 | RoW | M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine, Placebo | Bill & Melinda Gates Medical Research Institute, Wellcome Trust, Bill and Melinda Gates Foundation | Tuberculosis | 04/28 | 04/28 | | |
MESA-TB, NCT04556981: Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV |
|
|
| Completed | 2 | 402 | RoW | M72/AS01E Mycobacterium tuberculosis vaccine, Placebo | Bill & Melinda Gates Medical Research Institute, Wellcome Trust | Human Immunodeficiency Virus | 08/22 | 08/22 | | |
| 10E8.4/iMab / Bill & Melinda Gates Foundation, IAVI, TaiMed Biologics |
NCT03875209: 10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults |
|
|
| Completed | 1 | 54 | US | 10E8.4/iMab | David Ho, Bill and Melinda Gates Foundation, International AIDS Vaccine Initiative, The Emmes Company, LLC | HIV-1-infection | 03/22 | 03/22 | | |
NCT05890963: 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults |
|
|
| Recruiting | 1 | 20 | RoW | ART, antiretroviral therapy, 10E8.4/iMab, ibalizumab, VRC07-523LS, VRC01 variant | David Ho, Henry M. Jackson Foundation for the Advancement of Military Medicine, US Military HIV Research Program, National Institute of Allergy and infectious Diseases (NIAID)/Vaccine Research Center (VRC) | HIV-1-infection | 05/25 | 02/26 | | |
| BNT164a1 / BioNTech |
NCT05547464: Safety and Immune Responses After Vaccination with Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers |
|
|
| Active, not recruiting | 1/2 | 732 | RoW | BNT164a1, BNT164b1, Placebo | BioNTech SE | Tuberculosis | 06/26 | 05/27 | | |
NCT05537038: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers |
|
|
| Active, not recruiting | 1 | 120 | Europe | BNT164a1, BNT164b1, Placebo | BioNTech SE | Tuberculosis | 06/25 | 01/26 | | |
| IMC-M113V / Immunocore, Bill & Melinda Gates Foundation |
2021-002008-11: Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infection Estudio en fase I/II de IMC-M113V sobre la infección crónica por el VIH con supresión vírica |
|
|
| Ongoing | 1/2 | 53 | Europe | IMC-M113V, IMC-M113V, Concentrate for solution for infusion | Immunocore Limited, Immunocore Limited | Chronic HIV infection Infección crónica por el (VIH), HIV infection Infección (VIH), Diseases [C] - Virus Diseases [C02] | | | | |
| MAM01 / Atreca, Bill & Melinda Gates Foundation |
NCT06408857: Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population |
|
|
| Not yet recruiting | 1 | 139 | RoW | MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV, MAM01 190 mg SC, MAM01 225 mg SC, MAM01 150 mg SC, MAM01 100 mg SC, MAM01 150 mg IM, MAM01 150 mg IV, Placebo SC, Placebo IV, Placebo IM | Bill & Melinda Gates Medical Research Institute | Healthy Volunteers | 01/26 | 01/26 | | |
NCT05891236: Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults |
|
|
| Recruiting | 1 | 61 | US | MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg | Bill & Melinda Gates Medical Research Institute | Malaria | 12/24 | 06/25 | | |
